Blueprint Medicines (NASDAQ: BPMC) reported Q2 EPS of ($2.28), $0.14 worse than the analyst estimate of ($2.14). Revenue for the quarter came in at $8.3 million versus the consensus estimate of $6.94 million.

For earnings history and earnings-related data on Blueprint Medicines (BPMC) click here.